IFNA1 and synovial sarcoma: These results suggest that the development of anti-IFN-α mAbs offers an alternative approach, despite their potential, anti-IFN-α mAbs may face limitations in achieving substantial clinical benefits, which underscore the complexity of targeting IFN pathways in SS.